Comparative Analysis of BTK Inhibitors for CLL Therapy and Treatment Options

Part one of this episode explores questions in measurable residual disease (MRD) and chronic lymphocytic leukemia (CLL) with Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health.

“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies.